The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new ...
Pharmaceutical Executive spoke with Mark Talens, CCO of PAXAFE at LogiPharma 2026 in Boston. During the conversation., the ...
Just a few days after Astellas Pharma formally unveiled its new five-year corporate strategic plan in Tokyo in late May, Naoki Okamura, the global drugmaker’s representative dir ...
Precision medicine was once largely about making treatments more selective. From there, better structural understanding of ...
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts. IPO pricings bring two ...
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient ...
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the ...
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality ...
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy. Roche has added a twelfth US indication to Tecentriq (atezolizumab). The ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability ...
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results